Profile data is unavailable for this security.
About the company
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)454.44m
- Net income in CNY-26.45m
- Incorporated2005
- Employees1.04k
- LocationBeijing Hotgen Biotech Co LtdYard 26 Yongwang West Rd, Daxing DistBEIJING 102629ChinaCHN
- Phone+86 1 050973660
- Fax+86 1 056528861
- Websitehttp://www.hotgen.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GuiZhou YiBai Pharmaceutical Co., Ltd. | 2.71bn | -9.06m | 2.48bn | 5.51k | -- | 0.8265 | -- | 0.9149 | -0.0114 | -0.0114 | 3.42 | 3.79 | 0.56 | 1.47 | 11.26 | 491,815.10 | -0.4457 | 0.8618 | -0.6067 | 1.17 | 66.49 | 74.87 | -0.7958 | 1.45 | 1.32 | 1.67 | 0.2392 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
Ningbo Menovo Pharmaceutical Co Ltd | 1.23bn | -17.82m | 2.49bn | 2.35k | -- | 1.17 | -- | 2.02 | -0.0997 | -0.0997 | 5.23 | 9.99 | 0.2811 | 1.31 | 6.18 | 523,989.50 | -0.3253 | 4.94 | -0.4782 | 7.83 | 30.72 | 35.39 | -1.16 | 13.71 | 0.7935 | 0.7647 | 0.4042 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
Henan Taloph Pharmaceutical Stock Co Ltd | 2.01bn | 61.13m | 2.52bn | 2.35k | 42.89 | 1.54 | -- | 1.25 | 0.1024 | 0.1024 | 3.51 | 2.84 | 0.556 | 3.30 | 2.13 | 853,677.20 | 1.72 | 0.272 | 3.55 | 0.4981 | 26.76 | 27.97 | 3.09 | 0.5501 | 0.9283 | 2.02 | 0.3637 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
Beijing Hotgen Biotech Co Ltd | 454.44m | -26.45m | 2.57bn | 1.04k | -- | 0.7569 | -- | 5.64 | -0.3093 | -0.3093 | 5.14 | 36.65 | 0.1264 | 1.64 | 6.32 | 438,645.70 | -1.04 | 29.65 | -1.11 | 34.70 | 50.71 | 56.08 | -8.25 | 32.26 | 5.50 | -- | 0.0027 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
Jinan High-tech Development Co Ltd | 555.10m | -119.73m | 2.61bn | 716.00 | -- | 13.40 | -- | 4.70 | -0.1353 | -0.1353 | 0.6275 | 0.2201 | 0.1874 | 0.6198 | 0.6935 | 775,274.40 | -4.46 | -2.99 | -22.92 | -9.42 | 15.19 | 30.52 | -23.79 | -10.84 | 0.5687 | -- | 0.4146 | -- | -58.29 | -13.80 | -618.17 | -- | -35.45 | -- |
Chemclin Diagnostics Co Ltd | 455.80m | 150.93m | 2.69bn | 731.00 | 17.80 | 1.94 | -- | 5.90 | 0.3764 | 0.3764 | 1.14 | 3.45 | 0.2684 | 1.02 | 17.03 | 623,526.50 | 8.89 | 11.01 | 9.82 | 12.32 | 74.73 | 74.19 | 33.11 | 31.07 | 5.09 | -- | 0.1518 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
Data as of Jun 14 2024. Currency figures normalised to Beijing Hotgen Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 795.00k | 0.86% |
Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 680.32k | 0.74% |
Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 656.80k | 0.71% |
Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 611.06k | 0.66% |
Taikang Asset Management Co. Ltd.as of 31 Dec 2023 | 599.91k | 0.65% |
Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 231.07k | 0.25% |
Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 215.20k | 0.23% |
Huatai Securities (Shanghai) Asset Management Co., Ltd.as of 31 Dec 2023 | 205.71k | 0.22% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 157.51k | 0.17% |
Guolian Fund Management Co. Ltd.as of 31 Dec 2023 | 136.37k | 0.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.